

Answers for the Reviewer

Thank you for the reviewers' comments concerning our manuscript. Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval.

Revised portion are marked in red in the paper. The main corrections in the paper and the responds to the reviewer's comments areas flowing:

Reviewer #1:

Dear authors this is a very interesting manuscript as is proposes a new therapeutic strategy for LAPC. First, In this paper the authors aim to compare the therapeutic efficacy between conventional gemcitabine (GEM) plus concurrent IRE and GEM alone for locally advanced pancreatic cancer (LAPC). The authors found that GEM plus concurrent IRE resulted in significantly prolonging overall survival (19.8 mo) compared with chemotherapy alone. GEM plus concurrent IRE has a synergistic effect on the clinical treatment of LAPC. Second, The results section provided the relevant data after this new combination therapy. The discussion section gave emphasis to the new contribution of the study in its field. The authors stated that they performed no less than 30 min of an intravenous infusion of GEM (1,000 mg/m²) prior to IRE, which gave novelty to the study. Third, the limitations of the study were also described. As a preliminary exploration, this study has better clinical value and application prospects. Therefore, the manuscript presents sufficient quality to be published in this journal.

Response: Thanks for your positive comments.

We tried our best to improve the manuscript and made some changes in the

manuscript. These changes will not influence the content and framework of the paper. And here we did not list the changes but marked in red in revised paper.

We appreciate for Editors/Reviewers' warm work earnestly, and hope that the correction will meet with approval.

Yours sincerely,

Corresponding author:

Name: Lizhi Niu

E-mail: niuboshi@fudahospital.com